Recent advances in structure-based rational drug design.
Two approaches to structure-based drug design, that is, the docking of known compounds into a target protein and molecular assembly in situ, are seen to be merging technologies. The need for structural information about drug-protein complexes is now fundamental for drug discovery.
Gane
P J
PJ
De Novo Pharmaceuticals Ltd., Cambridge, UK. paul.gane@ddg.phar.cam.ac.uk
Dean
P M
PM
D000818:Animals; D015195:Drug Design; D006801:Humans; D015202:Protein Engineering; D013329:Structure-Activity Relationship